<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177732</url>
  </required_header>
  <id_info>
    <org_study_id>Calprotectin-N-telopeptides</org_study_id>
    <nct_id>NCT04177732</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy of Calprotectin and Cross-linked N-telopeptides</brief_title>
  <official_title>Assessment of Efficacy of Calprotectin and Cross-linked N-telopeptides of Type I Collagen Levels in Crevicular Fluid as a Biomarker in Patients With Peri-implantitis: A Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansour Assery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Riyadh Elm University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the efficacy of Calprotectin and cross-linked N-telopeptides of type
      I collagen levels in crevicular fluid as a biomarker in patients with peri-implantitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ethical approval will be obtained from the ethical committee of the Riyadh Elm University and
      written consent will be obtained from all the patients after explaining in detail the entire
      research protocol.

      Inclusion criteria for the present study:

        -  10 patients who underwent dental implant procedure five to ten years ago; among these- 5
           patients will be with healthy peri-implant status and 5 patients with presence of
           peri-implant diseases

        -  Patients of comparable age and gender distribution- Patients within the age group of 25
           to 45 years; and 3 males and 2 females in peri-implant diseases group and 3 males and 2
           females in healthy peri-implant status group

        -  Patients with negative history of any systemic illness, metabolic disease.

        -  Patients with negative history of antibiotic therapy in past ninety days.

      After collecting the PICF and GCF, examination of probing depth (PD), bleeding on probing
      (BOP) and gingival index (GI) will be done.Modified Löe and Silness criteria will be used for
      evaluating the GI score.Using modification of criteria described by Schei et al, bone loss
      rate of alveolar bone will be analyzed on radiographic assessment. Periodontal sites with PD
      of equal to or more than 3mm with GI score of equal to or more than 1mm and presence or
      absence of BOP, will be categorized as peri-implant disease sites. Periodontal sites with PD
      of less than 3mm with GI score of 0 and absence of BOP will be categorized as healthy implant
      sites. Sterile paper strips will be used for collecting PICF samples, followed by PICF sample
      preparation using modified criteria described previously in the literature. Isolation of the
      PICF sampling sites will be done using cotton roles. This will be followed by removal of
      supra-gingival plaques and gentle air drying. Insertion of the periopaper will be done into
      the peri-implant crevice and will be kept there for thirty seconds. Periotron will be used
      for measuring the volume of PICF. Further, all the samples will be sent to laboratory where
      ELISA technique will be used for measuring the calprotectin
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: Healthy peri-implant status Group B: Presence of peri-implant diseases</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Calprotectin concentration in GCF</measure>
    <time_frame>3 weeks</time_frame>
    <description>One of inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with bone inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-linked N-telopeptides concentration in GCF</measure>
    <time_frame>3 weeks</time_frame>
    <description>One of inflammation biomarkers found in gingival crevicular fluid (GCF) that are associated with bone inflammation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Peri-Implantitis</condition>
  <condition>Dental Implant Failed</condition>
  <arm_group>
    <arm_group_label>Healthy peri-implant status</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with healthy peri-implant status</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Presence of peri-implant diseases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with presence of peri-implant diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Collection of sulcular (crevicular) fluid</intervention_name>
    <description>Sterile paper strips will be used for collecting crevicular fluid</description>
    <arm_group_label>Healthy peri-implant status</arm_group_label>
    <arm_group_label>Presence of peri-implant diseases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Probing depth</intervention_name>
    <description>Williams SE manual probe will be used to measure the probing depth</description>
    <arm_group_label>Healthy peri-implant status</arm_group_label>
    <arm_group_label>Presence of peri-implant diseases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bleeding on probing</intervention_name>
    <description>Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction</description>
    <arm_group_label>Healthy peri-implant status</arm_group_label>
    <arm_group_label>Presence of peri-implant diseases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gingival index</intervention_name>
    <description>Modified Löe and Silness criteria will be used for evaluating the gingival index score</description>
    <arm_group_label>Healthy peri-implant status</arm_group_label>
    <arm_group_label>Presence of peri-implant diseases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bone loss rate of alveolar bone</intervention_name>
    <description>Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment</description>
    <arm_group_label>Healthy peri-implant status</arm_group_label>
    <arm_group_label>Presence of peri-implant diseases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  Patients with history of any systemic illness, metabolic disease.

          -  Patients with history of antibiotic therapy in past ninety days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Riyadh Elm University</investigator_affiliation>
    <investigator_full_name>Mansour Assery</investigator_full_name>
    <investigator_title>Consultant in Prosthodontics &amp; Dental Implant</investigator_title>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>Calprotectin</keyword>
  <keyword>Cross-linked N-telopeptides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

